Theriva Biologics (NYSEAMERICAN:TOVX) Trading 3.8% Higher – Still a Buy?

Shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) were up 3.8% on Thursday . The company traded as high as $0.2621 and last traded at $0.2525. Approximately 1,535,853 shares changed hands during mid-day trading, an increase of 188% from the average session volume of 532,729 shares. The stock had previously closed at $0.2432.

Theriva Biologics Price Performance

The firm has a market cap of $8.44 million, a PE ratio of -0.01 and a beta of 1.11. The stock’s fifty day moving average price is $0.23 and its 200-day moving average price is $0.25. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.13 and a quick ratio of 1.13.

Theriva Biologics (NYSEAMERICAN:TOVX) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.07) earnings per share for the quarter.

Institutional Investors Weigh In On Theriva Biologics

An institutional investor recently bought a new stake in Theriva Biologics stock. Two Sigma Investments LP acquired a new position in shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 61,837 shares of the company’s stock, valued at approximately $25,000. Two Sigma Investments LP owned approximately 0.64% of Theriva Biologics as of its most recent filing with the Securities & Exchange Commission. 6.17% of the stock is currently owned by hedge funds and other institutional investors.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.